DK1052974T3 - Farmaceutisk sammensætning indeholdende epothilon - Google Patents

Farmaceutisk sammensætning indeholdende epothilon

Info

Publication number
DK1052974T3
DK1052974T3 DK99907491T DK99907491T DK1052974T3 DK 1052974 T3 DK1052974 T3 DK 1052974T3 DK 99907491 T DK99907491 T DK 99907491T DK 99907491 T DK99907491 T DK 99907491T DK 1052974 T3 DK1052974 T3 DK 1052974T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical composition
composition containing
containing epothilone
epothilone
pharmaceutical
Prior art date
Application number
DK99907491T
Other languages
Danish (da)
English (en)
Inventor
Hoogevest Peter Van
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26313062&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1052974(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9802451.6A external-priority patent/GB9802451D0/en
Priority claimed from GBGB9813646.8A external-priority patent/GB9813646D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1052974T3 publication Critical patent/DK1052974T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK99907491T 1998-02-05 1999-02-03 Farmaceutisk sammensætning indeholdende epothilon DK1052974T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9802451.6A GB9802451D0 (en) 1998-02-05 1998-02-05 Organic compounds
GBGB9813646.8A GB9813646D0 (en) 1998-06-24 1998-06-24 Organic compounds
PCT/EP1999/000702 WO1999039694A2 (en) 1998-02-05 1999-02-03 Compositions containing organic compounds

Publications (1)

Publication Number Publication Date
DK1052974T3 true DK1052974T3 (da) 2009-08-10

Family

ID=26313062

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99907491T DK1052974T3 (da) 1998-02-05 1999-02-03 Farmaceutisk sammensætning indeholdende epothilon

Country Status (36)

Country Link
US (5) US20030203876A1 (cs)
EP (1) EP1052974B1 (cs)
JP (2) JP4644364B2 (cs)
KR (3) KR20060002022A (cs)
CN (2) CN1623543A (cs)
AR (1) AR017979A1 (cs)
AT (1) ATE431733T1 (cs)
AU (1) AU753519B2 (cs)
BE (1) BE1012140A3 (cs)
BR (1) BR9907647B1 (cs)
CA (1) CA2320182C (cs)
CL (1) CL2003002786A1 (cs)
CO (1) CO4920246A1 (cs)
CY (1) CY1109311T1 (cs)
CZ (1) CZ303168B6 (cs)
DE (1) DE69940904D1 (cs)
DK (1) DK1052974T3 (cs)
ES (1) ES2324378T3 (cs)
FR (1) FR2774909B1 (cs)
HU (1) HUP0101564A3 (cs)
ID (1) ID26549A (cs)
IL (2) IL137550A0 (cs)
IT (1) IT1313549B1 (cs)
MX (1) MXPA00007681A (cs)
MY (1) MY125921A (cs)
NO (2) NO329376B1 (cs)
NZ (1) NZ506389A (cs)
PE (1) PE20000272A1 (cs)
PL (1) PL201329B1 (cs)
PT (1) PT1052974E (cs)
RU (1) RU2214246C2 (cs)
SI (1) SI1052974T1 (cs)
SK (2) SK287775B6 (cs)
TR (1) TR200002299T2 (cs)
TW (1) TW457095B (cs)
WO (1) WO1999039694A2 (cs)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537579B1 (en) * 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
DE59609305D1 (de) 1995-11-17 2002-07-11 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Herstellung
DK0941227T5 (da) 1996-11-18 2009-10-05 Biotechnolog Forschung Gmbh Epothilon D, dens fremstilling samt dens anvendelse som cytostatisk middel og som plantebeskyttelsesmiddel
JP4579351B2 (ja) 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
GB9802451D0 (en) * 1998-02-05 1998-04-01 Ciba Geigy Ag Organic compounds
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6399638B1 (en) 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
IL143069A0 (en) 1998-11-20 2002-04-21 Kosan Biosciences Inc Recombinant methods and materials for producing epothilone and epothilone derivatives
US6518421B1 (en) * 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
US8618085B2 (en) * 2000-04-28 2013-12-31 Koasn Biosciences Incorporated Therapeutic formulations of desoxyepothilones
US6589968B2 (en) 2001-02-13 2003-07-08 Kosan Biosciences, Inc. Epothilone compounds and methods for making and using the same
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
YU58203A (sh) 2001-01-25 2006-08-17 Bristol-Myers Squibb Company Postupci primene epotilonskih analoga za lečenje kancera
PL367260A1 (en) 2001-01-25 2005-02-21 Bristol-Myers Squibb Company Parenteral formulation containing epothilone analogs
NZ526871A (en) 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
IL156578A0 (en) * 2001-01-25 2004-01-04 Bristol Myers Squibb Co A method for formulating an epothilone analog for pharmaceutical use and pharmaceutical preparations including an epothilone analog
US6893859B2 (en) 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
JP2004522774A (ja) 2001-02-20 2004-07-29 ブリストル−マイヤーズ　スクイブ　カンパニー エポチロン誘導体を用いる耐性腫瘍の治療
KR20040028720A (ko) 2001-02-20 2004-04-03 브리스톨-마이어스스퀴브컴파니 치료불응성 종양 치료용 에포틸론 유도체
IL157443A0 (en) * 2001-03-14 2004-03-28 Bristol Myers Squibb Co Pharmaceutical compositions for the treatment of cancer including an epothilone analog and a chemotherapeutic agent
PT1372650E (pt) * 2001-03-19 2009-02-25 Novartis Ag Associações compreendendo um agente antidiarreico e uma epotilona ou um derivado de epotilona
US6800653B2 (en) 2001-06-01 2004-10-05 Bristol-Myers Squibb Compnay Epothilone derivatives
AU2008203233B2 (en) * 2001-07-19 2010-04-29 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
TWI315982B (en) * 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
TWI341728B (en) 2002-01-14 2011-05-11 Novartis Ag Combinations comprising epothilones and anti-metabolites
AU2003218107A1 (en) 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
TW200403994A (en) 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
PL372070A1 (en) * 2002-06-10 2005-07-11 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
WO2003105828A1 (en) 2002-06-14 2003-12-24 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
DK1506203T3 (da) 2002-08-23 2007-05-14 Sloan Kettering Inst Cancer Syntese af epothiloner, mellemprodukter deraf, analoger deraf og anvendelser deraf
TWI291464B (en) 2002-09-23 2007-12-21 Bristol Myers Squibb Co Methods for the preparation, isolation and purification of epothilone B, and X-ray crystal structures of epothilone B
WO2004032866A2 (en) * 2002-10-09 2004-04-22 Kosan Biosciences, Inc. Therapeutic formulations
EP1553938B1 (en) * 2002-10-15 2007-01-03 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Use of epothilone derivatives for the treatment of hyperparathyroidism
EP2135868A1 (en) 2002-11-07 2009-12-23 Kosan Biosciences Incorporated Trans-9, 10-dehydroepothilone c and d, analogs thereof and methods of making the same
CA2539801A1 (en) * 2003-10-09 2005-04-21 Kosan Biosciences, Inc. Therapeutic formulations
MXPA06003835A (es) * 2003-10-09 2006-06-14 Kosan Biosciences Inc Formulaciones terapeuticas.
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US7655442B2 (en) 2004-01-29 2010-02-02 Eisai R&D Management Co., Ltd. Method for stabilizing macrolide compounds
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
EP1674098A1 (en) 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
CN100409846C (zh) * 2005-11-22 2008-08-13 菏泽睿鹰制药集团有限公司 一种埃坡霉素b脂质体制剂及应用
CA2658475A1 (en) 2006-08-16 2008-02-21 Novartis Ag Organic compounds
EP2210584A1 (en) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
CN101642453B (zh) * 2009-09-15 2011-03-16 湖南迪诺制药有限公司 一种含有埃坡霉素b的药物制剂
GB201505347D0 (en) * 2015-03-27 2015-05-13 Salupont Consulting Ltd Sterilisation of s-nitrosothiols
ES3024636T3 (en) * 2017-09-27 2025-06-04 Novartis Ag Parenteral formulation comprising siponimod

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) * 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
IL27947A (en) * 1967-05-09 1972-07-26 Weitzman J Method for the production of thermoplastic resin particles and of mixtures of such particles with additives
JPS56115855A (en) * 1980-02-19 1981-09-11 Toyota Motor Corp Method and apparatus for controlling ignition timing of engine
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
US4659696A (en) * 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
HU191101B (en) * 1983-02-14 1987-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups
IE62095B1 (en) * 1988-03-29 1994-12-14 Univ Florida Pharmaceutical formulations for parenteral use
FR2647343B1 (fr) * 1989-05-24 1994-05-06 Rhone Poulenc Sante Nouvelle forme pharmaceutique poreuse et sa preparation
US5216011A (en) * 1989-09-01 1993-06-01 Bristol-Myers Squibb Co. Stable solutions of mitomycin c
DE4138042C2 (de) * 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
CA2086874E (en) * 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
JPH0753396A (ja) * 1993-08-19 1995-02-28 Ensuiko Sugar Refining Co Ltd タキソールのサイクロデキストリン包接物，その製造法および用途
CA2092271C (en) * 1993-03-09 2009-10-13 Eddie Reed Use of g-csf for treating taxol side-effects
HU213200B (en) * 1993-05-12 1997-03-28 Chinoin Gyogyszer Es Vegyeszet The cyclodextrin or cyclodextrin derivative cluster complexes of taxol, taxotere, or taxus, pharmaceutical preparations containing them and process for their production
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
FR2718963B1 (fr) * 1994-04-25 1996-05-24 Rhone Poulenc Rorer Sa Nouvelle composition pharmaceutique à base de taxoïdes.
US5616330A (en) * 1994-07-19 1997-04-01 Hemagen/Pfc Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same
HUT73844A (en) * 1994-11-11 1996-09-30 Chinoin Gyogyszer Es Vegyeszet New taxol complexes and pharmaceutical compositions containing them
JP3934705B2 (ja) * 1995-05-26 2007-06-20 ノバルティス ファーマ株式会社 サイクロデキストリン組成物
DE59609305D1 (de) * 1995-11-17 2002-07-11 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Herstellung
NZ332234A (en) * 1996-03-12 2000-06-23 Pg Txl Company Lp Water soluble paclitaxel prodrugs formed by conjugating paclitaxel or docetaxel with a polyglutamic acid polymer and use for treating cancer
US5877205A (en) * 1996-06-28 1999-03-02 Board Of Regents, The University Of Texas System Parenteral paclitaxel in a stable non-toxic formulation
JP4579351B2 (ja) * 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
US6441186B1 (en) * 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs

Also Published As

Publication number Publication date
BE1012140A3 (fr) 2000-05-02
AR017979A1 (es) 2001-10-24
NO20100302L (no) 2000-10-04
MY125921A (en) 2006-08-30
CY1109311T1 (el) 2014-07-02
ID26549A (id) 2001-01-18
US20110124691A1 (en) 2011-05-26
ATE431733T1 (de) 2009-06-15
CN1292683A (zh) 2001-04-25
SK11702000A3 (sk) 2001-01-18
CO4920246A1 (es) 2000-05-29
CL2003002786A1 (es) 2005-02-04
PT1052974E (pt) 2009-08-07
NO20003930D0 (no) 2000-08-03
ITMI990208A1 (it) 2000-08-04
ES2324378T3 (es) 2009-08-05
DE69940904D1 (de) 2009-07-02
SK287487B6 (sk) 2010-11-08
KR20080016756A (ko) 2008-02-21
SI1052974T1 (sl) 2009-10-31
US20060127423A1 (en) 2006-06-15
AU753519B2 (en) 2002-10-17
WO1999039694A3 (en) 1999-09-23
PE20000272A1 (es) 2000-04-17
JP2010090147A (ja) 2010-04-22
IL137550A0 (en) 2001-07-24
NZ506389A (en) 2003-07-25
IT1313549B1 (it) 2002-09-09
AU2722699A (en) 1999-08-23
CN100396276C (zh) 2008-06-25
CA2320182A1 (en) 1999-08-12
EP1052974A2 (en) 2000-11-22
HUP0101564A3 (en) 2002-06-28
IL137550A (en) 2010-06-30
BR9907647B1 (pt) 2014-04-01
BR9907647A (pt) 2000-11-14
PL201329B1 (pl) 2009-03-31
MXPA00007681A (es) 2003-07-14
EP1052974B1 (en) 2009-05-20
KR100669174B1 (ko) 2007-01-17
CZ303168B6 (cs) 2012-05-09
CA2320182C (en) 2008-11-25
JP2002502810A (ja) 2002-01-29
NO329376B1 (no) 2010-10-04
FR2774909B1 (fr) 2000-07-28
KR20060002022A (ko) 2006-01-06
PL342629A1 (en) 2001-06-18
US20030203876A1 (en) 2003-10-30
TW457095B (en) 2001-10-01
FR2774909A1 (fr) 1999-08-20
CN1623543A (zh) 2005-06-08
WO1999039694A2 (en) 1999-08-12
SK287775B6 (sk) 2011-09-05
HK1033809A1 (en) 2001-09-28
TR200002299T2 (tr) 2000-11-21
US20070060627A1 (en) 2007-03-15
JP4644364B2 (ja) 2011-03-02
NO20003930L (no) 2000-10-04
CZ20002834A3 (cs) 2000-11-15
US20080221065A1 (en) 2008-09-11
RU2214246C2 (ru) 2003-10-20
KR20010040534A (ko) 2001-05-15
HUP0101564A2 (hu) 2001-11-28

Similar Documents

Publication Publication Date Title
DK1052974T3 (da) Farmaceutisk sammensætning indeholdende epothilon
ID27415A (id) Komposisi farmaseutik
NO20005913D0 (no) Legemiddelsammensetning
ID26982A (id) Komposisi farmasi topiramat
DE69924999D1 (de) Lipasehemmer enthaltende pharmazeutische zusammensetzungen
IS5046A (is) Lyfjasamsetningar
NO20015175D0 (no) Farmasöytisk sammensetning
FI991485L (fi) Uusi farmaseuttinen koostumus
ID29262A (id) Komposisi farmasi
ID22891A (id) Komposisi farmasi untuk kombinasi piperidinoalkanol-dekongestan
ID26720A (id) Komposisi oral
ID26186A (id) Komposisi sampo
ID28694A (id) Komposisi sampo
ID27201A (id) Komposisi farmasi
DE69942892D1 (de) Gaserzeugende zusammensetzung
DE69928862D1 (de) Zusammensetzung
ITMI982222A0 (it) Composizioni farmaceutiche orali contenenti buprenorfina
ID27150A (id) Sediaan levotiroksin bahan farmasi
TR199903132A3 (tr) Metalosan bilesiklerinin aktive edici kompozisyonu.
ID29294A (id) Komposisi farmasi
PT1227817E (pt) Composicao farmaceutica aquosa contendo ciclesonida
FI4488U1 (fi) Farmaseuttinen koostumus
EE200100281A (et) Analgeetiline ravimkoostis
ATE297187T1 (de) Resorcinenthaltende zusammensetzung
ID25857A (id) Komposisi farmasi